Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany.
Institute of Metabolism and Systems Research (IMSR), and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham, Birmingham, UK.
Diabet Med. 2023 Dec;40(12):e15220. doi: 10.1111/dme.15220. Epub 2023 Sep 21.
We previously developed, synthesized and tested light-activated sulfonylureas for optical control of K channels and pancreatic beta cell activity in vitro and in vivo. Such technology relies on installation of azobenzene photoswitches onto the sulfonylurea backbone, affording light-dependent isomerization, alteration in ligand affinity for SUR1 and hence K channel conductance. Inspired by molecular dynamics simulations and to further improve photoswitching characteristics, we set out to develop a novel push-pull closed ring azobenzene unit, before installing this on the sulfonylurea glimepiride as a small molecule recipient. Three fine-tuned, light-activated sulfonylureas were synthesized, encompassing azetidine, pyrrolidine and piperidine closed rings. Azetidine-, pyrrolidine- and piperidine-based sulfonylureas all increased beta cell Ca -spiking activity upon continuous blue light illumination, similarly to first generation JB253. Notably, the pyrrolidine-based sulfonylurea showed superior switch OFF performance to JB253. As such, third generation sulfonylureas afford more precise optical control over primary pancreatic beta cells, and showcase the potential of pyrrolidine-azobenzenes as chemical photoswitches across drug classes.
我们之前开发、合成并测试了光激活的磺酰脲类药物,用于体外和体内光学控制 K 通道和胰腺β细胞的活性。这种技术依赖于将偶氮苯光开关安装到磺酰脲骨架上,从而实现光依赖性异构化、改变 SUR1 的配体亲和力,从而改变 K 通道电导。受分子动力学模拟的启发,并进一步改善光开关特性,我们着手开发一种新型的推拉闭环偶氮苯单元,然后将其安装在磺酰脲格列美脲上作为小分子受体。我们合成了三种经过精细调整的光激活磺酰脲类药物,包括氮杂环丁烷、吡咯烷和哌啶闭环。与第一代 JB253 类似,氮杂环丁烷、吡咯烷和哌啶基磺酰脲类药物在连续蓝光照射下均能增加β细胞 Ca 爆发活性。值得注意的是,基于吡咯烷的磺酰脲类药物的关闭性能优于 JB253。因此,第三代磺酰脲类药物能够更精确地对原代胰腺β细胞进行光学控制,并展示了吡咯烷偶氮苯作为跨药物类别的化学光开关的潜力。